Cybin Inc. partners with Thermo Fisher Scientific for manufacturing of CYB003, a deuterated psilocin treatment for major depressive disorder. Silo Pharma Inc. collaborates with Veloxity Labs for bioanalysis supporting a PTSD treatment, while NRx Pharmaceuticals reports financial results post the acquisition of Kadima Neuropsychiatry Institute. All three companies focus on developing psychedelic-based therapeutics for mental health conditions.